(Total Views: 371)
Posted On: 05/26/2022 7:47:44 AM
Post# of 55
SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!
$SIGA
Siga Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company scored an FDA approval for its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). Given the rise of Monkeypox cases around the globe, can the Company leverage its expertise to make the most of the emerging opportunity?
Read on to find out more!
https://www.aviseanalytics.com/sigas-smallpox...-business/
$SIGA
Siga Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company scored an FDA approval for its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). Given the rise of Monkeypox cases around the globe, can the Company leverage its expertise to make the most of the emerging opportunity?
Read on to find out more!
https://www.aviseanalytics.com/sigas-smallpox...-business/
(0)
(0)Scroll down for more posts ▼
